Colobreathe is a specialized inhaled antibacterial commonly used to help with the long-term management of chronic pulmonary infections in patients with Cystic Fibrosis (CF). Its role is focused on helping manage the infectious source in conditions where functional stability becomes affected.

Colobreathe is commonly used to help with the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older. This therapy is used primarily for established chronic colonization, helping with conditions characterized by periods of heightened symptoms and recurrent pulmonary exacerbations.

---

Quick Fact: Relief for Recurrent Exacerbations

Benefit Focus	Description
Therapeutic Use Focus	Chronic lung infection caused by P. aeruginosa
Symptom Focus	Frequency of recurrent respiratory flare-ups
Patient Benefit	Supports maintenance of functional stability

---

The long-term suppressive treatment may assist with managing the frequency and severity of symptoms that become more disruptive during flare-ups, such as increased cough and sputum changes. By providing supportive relief, the treatment contributes to improved comfort during periods of heightened symptoms and helps support the patient's routine.

“The treatment may be part of symptomatic management within the maintenance regimen, applied in contexts where additional symptomatic support is needed.”

Regulatory References

1. EMA therapeutic overview on Colobreathe

Who Can and Cannot Use Colobreathe?

This section details the official population eligibility and non-eligibility for Colobreathe (colistimethate sodium dry powder for inhalation), based strictly on governmental regulatory labeling. The medicine is primarily intended for patients with Cystic Fibrosis who have a chronic pulmonary infection caused by Pseudomonas aeruginosa.

---

Absolute Contraindications (Who Must Not Use)

Classification	Population	Status
Hypersensitivity	Patients with a known allergy to colistimethate sodium, colistin, or any excipients.	Contraindicated

---

Age-Related and Conditional Use

Official labeling defines strict boundaries for use based on age and pre-existing conditions:

• Approved Age: Colobreathe is approved for patients aged six years and older.
• Pediatric Restriction: Use is not recommended in children under six years of age due to insufficient safety and efficacy data in that group.
• Renal Impairment: Patients with kidney problems (renal impairment) must use the medicine with caution.
• Neurological Conditions: Use requires extreme caution in patients with myasthenia gravis.
• Reproductive Status: The medicine is not recommended for use by women who are pregnant or breastfeeding.

The official regulatory profile for Colobreathe is structured around managing risks related to additive toxicity and the sequential administration of respiratory treatments.

Additive Toxicity and Potentiation Risk

Co-administration with other formulations of colistimethate sodium, including parenteral or nebulised products, must be avoided due to the possibility of summative toxicity, which carries a risk of neurotoxicity and nephrotoxicity. A similar restriction applies to co-treatment with other potentially nephrotoxic or neurotoxic medicinal products, such as aminoglycoside antibiotics.

The interaction profile also documents a pharmacodynamic risk: the combination with neuromuscular blocking agents, including curariform agents, requires caution because of the potential for an enhanced neuromuscular blockade. Furthermore, co-treatment with macrolides (such as azithromycin) or fluoroquinolones (such as ciprofloxacin) requires extreme caution when administered to patients with myasthenia gravis, due to the established risk of potentiating neuromuscular effects.

Administration Sequence and Metabolic Profile

Regarding interactions related to administration, the regulatory labeling establishes a mandatory sequence for a complex inhaled regimen. Colobreathe must be administered as the final component after completing any prescribed inhaled bronchodilators, chest physiotherapy, and all other inhaled medicines.

Concerning metabolic clearance, official documentation states that Colistimethate sodium and colistin do not induce the activity of major Cytochrome P450 enzymes based on in-vitro testing, and no in-vivo interaction studies have been performed.

Colobreathe delivers colistimethate sodium (CMS) as a dry powder into the pulmonary airways. CMS functions as an inactive prodrug which undergoes hydrolysis to yield the active cationic lipopeptide, colistin. This conversion process is concentration-dependent within the lung environment.

Colistin's biological targets are the outer and cytoplasmic membranes of Gram-negative bacteria. The interaction type is primarily a membrane-disruptor, facilitated by electrostatic attraction between the polycationic colistin molecule and the anionic phosphate groups present on the lipid A moiety of the bacterial lipopolysaccharide (LPS) layer. This initial binding displaces divalent cations, specifically Ca^2+ and Mg^2+, that normally stabilize the outer membrane structure. This destabilization facilitates colistin's permeation across the outer membrane.

Upon reaching the inner bacterial membrane, colistin integrates its lipophilic fatty acyl side chain into the bilayer. This integration disrupts the integrity and permeability of the inner membrane, causing leakage of intracellular contents and the cessation of cellular function. The system-level consequence is modulation of bacterial population density through concentration-dependent bactericidal activity localized within the respiratory tract.

How Colobreathe is Used: Administration Guidelines

Colobreathe (colistimethate sodium dry powder) is an inhaled medicine used as part of a long-term plan for managing chronic lung infections. Usage instructions define the administration parameters, including the route, the specific device, and the required dosing pattern.

---

Administration and Dosage Regimen

Instruction	Detail
Route of Administration	Strictly by inhalation (pulmonary route)
Dosing Schedule	One capsule (1,662,500 International Units, or 125 mg) per administration
Frequency	Twice daily, maintaining a dose interval of approximately 12 hours

---

Procedural Conditions and Use Protocol

The dry powder contained in the hard capsule must only be administered using the dedicated Turbospin dry powder inhaler device. To ensure correct usage, the first administration should occur under medical supervision. If the patient uses other inhaled treatments or performs chest physiotherapy, Colobreathe must be taken last in the sequence of care.

Patients 6 years of age and older use the same prescribed dose. No dose adjustment is considered necessary for patients with impaired kidney or liver function. Following inhalation, the patient must rinse the mouth well with water and spit out (without swallowing the rinse water) as a mandatory step in the administration protocol.

Colobreathe: Recent Clinical Evidence

Evidence for Use in Chronic P. aeruginosa Infection

Research on Colobreathe was studied for its role in managing chronic pulmonary infections caused by the bacterium Pseudomonas aeruginosa in individuals with cystic fibrosis (CF). The primary evidence was derived from a single, short-term (24-week) clinical trial that studied patients who already had an established, persistent infection.

Core Outcomes and Comparator Studies

The main goal of this pivotal trial was to monitor and measure changes in lung function (FEV1% predicted), as well as the frequency of acute respiratory flare-ups and patient-reported outcomes describing perceived discomfort. The study was designed to compare the dry powder inhalation against an existing standard of care (a different nebulised antibiotic).

The core trial reported measurements of lung function and examined non-inferiority compared to the measurements observed with the standard nebulised treatment over the 24 weeks. This study was an open-label design, meaning participants and staff knew which treatment was being received.

Study Duration and Populations

The research was evaluated in a specific population, including individuals aged six years and older who were clinically stable and had chronic infection. The primary clinical evidence is limited because the main trial follow-up duration was restricted to 6 months (24 weeks).

Since chronic P. aeruginosa infection is a condition characterized by cycles of stability and flare-ups, long-term effects are not fully established based on controlled evidence. Subsequent analyses from post-marketing and patient registry settings contribute to understanding treatment patterns over longer time intervals, but data are still emerging.

Research Gaps and Uncertainty

Scientific evaluation highlights areas where certainty remains low. The short follow-up duration was limited for assessing a chronic condition. Additionally, comparative evidence is lacking for a direct, head-to-head comparison against the nebulised formulation of colistimethate sodium itself (the same drug, but in a different delivery system). The research provides context but not individual predictions, meaning the data highlights what is known and what is still uncertain.

Key Studies & References

1. Colistimethate sodium dry powder for inhalation (Colobreathe) for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis: a technology appraisal (NIHR HTA)

Storage and Disposal Instructions for Colobreathe

Colobreathe (colistimethate sodium inhalation powder, hard capsules) must be stored under specific environmental and container conditions defined by regulatory authorities.

---

Storage Conditions

The medicine must not be stored above 25 C and must be kept in the original package to protect from moisture. The capsules are for immediate, single use; a capsule must be discarded if its protective foil is peeled back but the capsule is not used right away. Colobreathe must be stored out of the sight and reach of children and must not be administered after the marked expiry date.

---

Disposal Instructions

There are no special requirements for the disposal of the capsules themselves. However, the accompanying Turbospin inhalation device must be discarded after the completion of the treatment pack. Any unused or expired medicine and associated waste materials must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.